Hoffman S J, Robinson W A
Division of Medical Oncology, University of Colorado Health Sciences Center, Denver 80262.
Am J Hematol. 1988 Jun;28(2):124-7. doi: 10.1002/ajh.2830280214.
The use of chemical agents that induce differentiation of malignant cells to normal cells has held great promise as an adjunct to standard chemotherapy. In vitro data has shown that 13-cis-retinoic acid can differentiate certain leukemia cell lines (e.g., HL-60) into stable granulocyte cells. In this study, oral 13-cis-retinoic acid was administered to four patients with the myelodysplastic syndrome (MDS) and to four patients with acute nonlymphocytic leukemia (ANLL). None of the MDS patients showed an hematologic response to the drug, while three of four ANLL patients responded with normalized peripheral blood counts. The side effects of the drug at 80-120 mg/d (dry skin, cheilitis, epistaxis) were self limiting.
使用能诱导恶性细胞分化为正常细胞的化学制剂作为标准化疗的辅助手段，已展现出巨大前景。体外数据表明，13 - 顺式维甲酸可将某些白血病细胞系（如HL - 60）分化为稳定的粒细胞。在本研究中，对4例骨髓增生异常综合征（MDS）患者和4例急性非淋巴细胞白血病（ANLL）患者给予口服13 - 顺式维甲酸。MDS患者中无一例对该药物有血液学反应，而4例ANLL患者中有3例出现外周血细胞计数恢复正常的反应。该药物在80 - 120 mg/d剂量时的副作用（皮肤干燥、唇炎、鼻出血）为自限性。
